Search

Your search keyword '"Ciccullo, A"' showing total 733 results
Start Over Author "Ciccullo, A"
733 results on '"Ciccullo, A"'

51. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study

Author

Lagi, Filippo, primary, Giacomelli, Andrea, additional, Borghi, Vanni, additional, Ciccullo, Arturo, additional, Taramasso, Lucia, additional, Madeddu, Giordano, additional, D'Ettorre, Gabriella, additional, Giacometti, Andrea, additional, Ducci, Filippo, additional, De Vito, Andrea, additional, Pincino, Rachele, additional, Di Giambenedetto, Simona, additional, Mussini, Cristina, additional, Antinori, Spinello, additional, and Sterrantino, Gaetana, additional

Published
2023
Full Text
View/download PDF

52. Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults

Author

Simone Belmonti, Barbara Rossetti, Sara Modica, Lorenzo Paglicci, Alberto Borghetti, Arturo Ciccullo, Chiara Picarelli, Roberto Cauda, Andrea De Luca, Francesca Montagnani, and Francesca Lombardi

Subjects
HIV, PCV13, Pneumococcal vaccination, PPV23, Serologic response, Streptococcus pneumoniae, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Introduction Long-term comparative immunologic response to 13-valent pneumococcal conjugate vaccine (PCV13) versus 23-valent polysaccharide vaccine (PPV23) among HIV-infected adults has not yet been investigated. Methods In this prospective pilot study, we quantified in HIV-positive adults serotype-specific IgG concentrations of the 12 pneumococcal serotypes shared by both vaccines 5 years after vaccination with two doses of PCV13 8 weeks apart (group 1) or one dose of PPV23 (group 2) and compared them with those assessed prior to vaccination (BL) and after 1 year (T1). Comparison of immunogenicity was based on geometric mean concentration (GMC), proportion of individuals with ≥ twofold increase from BL in specific antibody concentration against ≥ 2 serotypes and percentage of individuals with serotype-specific IgG ≥ 0.35 μg/ml, ≥ 1 μg/ml and ≥ individual serotype-specific correlates of protection. Results We included 91 subjects (median CD4+ 650 cells/µl, > 90% with HIV-RNA

Published
2019
Full Text
View/download PDF

53. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients

Author

Francesca Lombardi, Simone Belmonti, Alberto Borghetti, Arturo Ciccullo, Gianmaria Baldin, Roberto Cauda, Massimiliano Fabbiani, and Simona Di Giambenedetto

Subjects
hiv, inflammation, inflammatory biomarkers, dual therapy, dolutegravir, scd14, Infectious and parasitic diseases, RC109-216
Abstract

Background: HIV-induced systemic immune activation and inflammation have been associated with morbidity and mortality in virologically suppressed patients. Objective: To evaluate the impact of treatment switch from a dual regimen with lamivudine (3TC) plus ritonavir-boosted protease inhibitors (PI/r) to 3TC plus dolutegravir (DTG) on the monocyte activation marker soluble CD14 (sCD14) and other inflammatory biomarkers, interleukin-6 (IL-6), C-reactive protein (CRP), intestinal fatty acid–binding protein (I-FABP) and D-dimer. Methods: We performed a retrospective case-crossover study on integrase inhibitors-naïve virologically suppressed patients while on 3TC + PI/r dual maintenance therapy for ≥48 weeks who switched to 3TC + DTG and maintained this regimen for ≥48 weeks. Biomarkers plasma levels were tested by ELISA assays on stored samples at three time points: at switch (BL), 48 weeks before (−48 W) and 48 weeks after switch (+48 W). Results: A total of 67 patients were included. Median sCD14 levels were stable from −48 W to BL (from 6.07 to 6.04 log10 pg/mL, p = 0.235) but showed a statistically significant decrease after switch: from 6.04 (IQR 5.92-6.12) at BL to 5.95 (IQR 5.84–6.07) log10 pg/mL at + W48 (p

Published
2019
Full Text
View/download PDF

54. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Author

Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, and Simona Di Giambenedetto

Subjects
HIV, Antiretroviral therapy, Maintenance therapy, Dual therapy, Lamivudine, Dolutegravir, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking. Methods Time to treatment discontinuation (TD) and virological failure (VF) were compared in a cohort of HIV+ patients on a virologically-effective ART starting lamivudine with either darunavir/r, atazanavir/r or dolutegravir. Changes in laboratory parameters were also evaluated. Results Four-hundred-ninety-four patients were analyzed (170 switching to darunavir/r, 141 to atazanavir/r, 183 to dolutegravir): median age was 49 years, with 8 years since ART start. Groups differed for age, HIV-risk factor, time since HIV-diagnosis and on ART, previous therapy and reasons for switching. Estimated proportions free from TD at week 48 and 96 were 79.8 and 48.3% of patients with darunavir/r, 87.0 and 70.9% with atazanavir/r, and 88.2 and 82.6% with dolutegravir, respectively (p

Published
2019
Full Text
View/download PDF

58. Designing circular supply chains in start-up companies: evidence from Italian fashion and construction start-ups

Author

Federica Ciccullo, Margherita Pero, and Andrea S. Patrucco

Subjects
Transportation, Business and International Management
Abstract

PurposeThe theory of complex adaptive systems (CASs) represents an interesting perspective to study the characteristics of circular supply chains (CSCs). In this regard, the current literature lacks evidence regarding coordination and integration mechanisms, characteristics of the environment and emerging system properties of CSCs. This paper aims to fill this gap and focuses on how and why companies design (i.e. configure and coordinate) their CSCs and what value these design choices help to create across different industries.Design/methodology/approachThe authors use a multiple case study approach and analyze data collected from a sample of five sustainable start-ups operating in the fashion and construction industries in Italy to better understand how these companies design (i.e. configure and coordinate) their CSCs.FindingsResults reveal that in the two industries under investigation, the design of CSCs built around open and closed–loop logic is triggered by the intention to solve a negative sustainability impact. The sustainability impact determines whether the value is restored within the same supply chain, in another, or inside or outside the same industry. Interestingly, start-ups appear to coordinate other CSC actors with three leading roles: (1) orchestrator, (2) integrated orchestrator and (3) circular manufacturer. The coordination role of the start-ups differs in each supply chain configuration based on the level of vertical integration of manufacturing activities.Originality/valueFrom a theoretical perspective, the authors' results expand previous supply chain management (SCM) literature by presenting an empirical analysis of the configuration and coordination of CSCs, and discussing the drivers for creating such circularity from a CAS perspective. From a managerial perspective, the authors offer a practical experience to entrepreneurs on how to transform circular and sustainable business model aspirations into CSC practices.

Published
2023

59. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort

Author

Arturo Ciccullo, Gianmaria Baldin, Vanni Borghi, Filippo Lagi, Alessandra Latini, Gabriella d’Ettorre, Letizia Oreni, Paolo Fusco, Amedeo Capetti, Massimiliano Fabbiani, Andrea Giacomelli, Alessandro Grimaldi, Giordano Madeddu, Gaetana Sterrantino, Cristina Mussini, and Simona Di Giambenedetto

Subjects
HIV, HAART, dolutegravir, toxicity, Microbiology, QR1-502
Abstract

Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank p < 0.001). At a multivariate analysis, a longer time of virological suppression (aHR 0.994, p < 0.001) and having experienced a previous virological failure (aHR 0.788, p = 0.016) resulted protective against DTG discontinuation. Most discontinuations (84.0%) happened within the first 12 months of DTG initiation, in particular, 92.2% of discontinuations due to neuropsychiatric toxicity were observed in the first year. Our data confirm the overall good tolerability of DTG in clinical practice, with a low rate of discontinuations. CNS toxicity resulted the main reason for DTG discontinuation, with most related interruptions happening in the first year from DTG introduction.

Published
2022
Full Text
View/download PDF

60. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy

Author

Fabbiani, Massimiliano, Borghetti, Alberto, Squillace, Nicola, Colafigli, Manuela, Taramasso, Lucia, Lombardi, Andrea, Rossetti, Barbara, Ciccullo, Arturo, Colella, Elisa, Picarelli, Chiara, Berruti, Marco, Latini, Alessandra, Montagnani, Francesca, Sambo, Margherita, Di Biagio, Antonio, Gori, Andrea, Di Giambenedetto, Simona, and Bandera, Alessandra

Published
2021
Full Text
View/download PDF

62. Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic

Author

Delle Donne, Valentina, primary, Massaroni, Valentina, additional, Borghetti, Alberto, additional, Ciccullo, Arturo, additional, Dusina, Alex, additional, Lombardi, Francesca, additional, Steiner, Rebecca Jo, additional, Iannone, Valentina, additional, Salvo, Pierluigi Francesco, additional, and Di Giambenedetto, Simona, additional

Published
2023
Full Text
View/download PDF

64. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Author

Borghetti, Alberto, Lombardi, Francesca, Gagliardini, Roberta, Baldin, Gianmaria, Ciccullo, Arturo, Moschese, Davide, Emiliozzi, Arianna, Belmonti, Simone, Lamonica, Silvia, Montagnani, Francesca, Visconti, Elena, De Luca, Andrea, and Di Giambenedetto, Simona

Published
2019
Full Text
View/download PDF

65. Automated Quantitative Lung CT Improves Prognostication in Non-ICU COVID-19 Patients beyond Conventional Biomarkers of Disease

Author

Pierpaolo Palumbo, Maria Michela Palumbo, Federico Bruno, Giovanna Picchi, Antonio Iacopino, Chiara Acanfora, Ferruccio Sgalambro, Francesco Arrigoni, Arturo Ciccullo, Benedetta Cosimini, Alessandra Splendiani, Antonio Barile, Francesco Masedu, Alessandro Grimaldi, Ernesto Di Cesare, and Carlo Masciocchi

Subjects
COVID-19, lung inflammation, prognosis, tomography computed scanners, lung volume measurement, Medicine (General), R5-920
Abstract

(1) Background: COVID-19 continues to represent a worrying pandemic. Despite the high percentage of non-severe illness, a wide clinical variability is often reported in real-world practice. Accurate predictors of disease aggressiveness, however, are still lacking. The purpose of our study was to evaluate the impact of quantitative analysis of lung computed tomography (CT) on non-intensive care unit (ICU) COVID-19 patients’ prognostication; (2) Methods: Our historical prospective study included fifty-five COVID-19 patients consecutively submitted to unenhanced lung CT. Primary outcomes were recorded during hospitalization, including composite ICU admission for the need of mechanical ventilation and/or death occurrence. CT examinations were retrospectively evaluated to automatically calculate differently aerated lung tissues (i.e., overinflated, well-aerated, poorly aerated, and non-aerated tissue). Scores based on the percentage of lung weight and volume were also calculated; (3) Results: Patients who reported disease progression showed lower total lung volume. Inflammatory indices correlated with indices of respiratory failure and high-density areas. Moreover, non-aerated and poorly aerated lung tissue resulted significantly higher in patients with disease progression. Notably, non-aerated lung tissue was independently associated with disease progression (HR: 1.02; p-value: 0.046). When different predictive models including clinical, laboratoristic, and CT findings were analyzed, the best predictive validity was reached by the model that included non-aerated tissue (C-index: 0.97; p-value: 0.0001); (4) Conclusions: Quantitative lung CT offers wide advantages in COVID-19 disease stratification. Non-aerated lung tissue is more likely to occur with severe inflammation status, turning out to be a strong predictor for disease aggressiveness; therefore, it should be included in the predictive model of COVID-19 patients.

Published
2021
Full Text
View/download PDF

68. The effect of switching to Maraviroc + Darunavir/ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study

Author

Rossetti, B., Gagliardini, R., Sterrantino, G., Colangeli, V., Latini, A., Colafigli, M., Vignale, F., Rusconi, S., Di Biagio, A., Orofino, G., Mezzaroma, I., Vullo, V., Francisci, D., Mastroianni, C., Trezzi, M., Canovari, B., Lamonica, S., Ciccullo, A., Borghetti, A., D’Arminio Monforte, A., Di Giambenedetto, S., and De Luca, A.

Published
2019
Full Text
View/download PDF

70. Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak

Author

Francesca Lombardi, Rosalba Ricci, Simone Belmonti, Massimiliano Fabbiani, Alberto Borghetti, Gianmaria Baldin, Arturo Ciccullo, Enrica Tamburrini, Elena Visconti, Maurizio Sanguinetti, and Simona Di Giambenedetto

Subjects
HIV, SARS-CoV-2, COVID-19, seroprevalence, antiretroviral therapy, Medicine (General), R5-920
Abstract

Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March–June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37–1.42). Conclusion: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population.

Published
2021
Full Text
View/download PDF

71. Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV

Author

Valentina Delle Donne, Valentina Massaroni, Nicoletta Ciccarelli, Francesca Lombardi, Alberto Borghetti, Arturo Ciccullo, Alex Dusina, Damiano Farinacci, Ganmaria Baldin, Elena Visconti, Enrica Tamburrini, and Simona Di Giambenedetto

Subjects
Male, Settore M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA, HIV Infections, Cohort Studies, Cellular and Molecular Neuroscience, Cross-Sectional Studies, Anti-Retroviral Agents, Neurology, HIV · HIV-associated neurocognitive disorders · Sex differences · Neurocognition · Cognition evaluation, Virology, Humans, Female, Neurology (clinical), Retrospective Studies
Abstract

Based on the available literature, women living with HIV (WLWH) seem to show greater cognitive and emotional disadvantages than men living with HIV (MLWH). Our aim was to compare the cognitive performance of MLWH and WLWH in an Italian cohort of People Living With HIV (PLWH) and to analyse factors potentially contributing to sex differences in cognitive function. We ran a retrospective, cross-sectional analysis of a monocentric dataset of PLWH who were administered a standardized neuropsychological test battery (SNB) during routine clinical care. We enrolled 161 Italian PLWH who are on combined antiretroviral therapy (cART): 114 (70.8%) MLWH and 47 (29.2%) WLWH.Global cognitive performance (composite z score) (GCP) was significantly higher in MLWH than WLWH [mean 0.19 (SD 0.85) vs − 0.13 (SD 0.96); p = 0.039]. Moreover, WLWH obtained significantly higher scores on the Zung Depression Scale than MLWH [mean 41.8 (SD 10.9) vs 36.7 (SD 9.2); p = 0.003]. However, there was no statistically significant direct effect between male sex and better GCP (p = 0.692) in the context of a mediation model. On the contrary, the associations between male sex and better GCP were mediated by higher level of education (a*b = + 0.15, Bootstrap CI95 = 0.05 and 0.27) and a lower Zung depression score (a*b = + 0.10, Bootstrap CI95 = 0.02 and 0.21).In conclusion, the global cognitive performance of WLWH is lower than that of MLWH. However, other demographic and clinical factors besides sex might help explain differences in their neurocognitive functions and make it possible for us to monitor them and identify those patients most in need.

Published
2022

72. Rapid improvement of severe Mpox lesions with oral tecovirimat

Author

Raccagni, Angelo Roberto, primary, Leoni, Davide, additional, Ciccullo, Arturo, additional, Verdenelli, Stefano, additional, Cattelan, Anna Maria, additional, Di Giambenedetto, Simona, additional, Falcone, Marco, additional, Mileto, Davide, additional, Castagna, Antonella, additional, and Nozza, Silvia, additional

Published
2023
Full Text
View/download PDF

74. Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Author

Fabbiani, Massimiliano, primary, Masini, Melissa, additional, Rossetti, Barbara, additional, Ciccullo, Arturo, additional, Borghi, Vanni, additional, Lagi, Filippo, additional, Capetti, Amedeo, additional, Colafigli, Manuela, additional, Panza, Francesca, additional, Baldin, Gianmaria, additional, Mussini, Cristina, additional, Sterrantino, Gaetana, additional, Farinacci, Damiano, additional, Montagnani, Francesca, additional, Tumbarello, Mario, additional, and Di Giambenedetto, Simona, additional

Published
2023
Full Text
View/download PDF

75. Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen

Author

Iannone, Valentina, primary, Passerotto, Rosa Anna, additional, Lamanna, Francesco, additional, Steiner, Rebecca Jo, additional, Lombardi, Francesca, additional, Salvo, Pierluigi Francesco, additional, Dusina, Alex, additional, Farinacci, Damiano, additional, Borghetti, Alberto, additional, Di Giambenedetto, Simona, additional, and Ciccullo, Arturo, additional

Published
2023
Full Text
View/download PDF

77. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype

Author

Salvo, Pierluigi Francesco, primary, Farinacci, Damiano, additional, Ciccullo, Arturo, additional, Borghi, Vanni, additional, Rusconi, Stefano, additional, Saracino, Annalisa, additional, Gennari, William, additional, Bruzzone, Bianca, additional, Vicenti, Ilaria, additional, Callegaro, Annapaola, additional, Di Biagio, Antonio, additional, Zazzi, Maurizio, additional, Di Giambenedetto, Simona, additional, and Borghetti, Alberto, additional

Published
2023
Full Text
View/download PDF

78. Malnutrition in COVID-19 survivors: prevalence and risk factors

Author

Tosato, Matteo, Calvani, Riccardo, Ciciarello, Francesca, Galluzzo, Vincenzo, Martone, Anna Maria, Zazzara, Maria Beatrice, Pais, Cristina, Savera, Giulia, Camprubi Robles, Maria, Ramirez, Maria, Landi, Francesco, Gremese, Elisa, Bernabei, Roberto, Fantoni, Massimo, Gasbarrini, Antonio, Romano Settanni, Carlo, Porcari, Serena, Benvenuto, Francesca, Bramato, Giulia, Brandi, Vincenzo, Carfì, Angelo, Rita Lo Monaco, Maria, Maria Martone, Anna, Marzetti, Emanuele, Napolitano, Carmen, Pagano, Francesco, Rocchi, Sara, Rota, Elisabetta, Salerno, Andrea, Tritto, Marcello, Beatrice Zazzara, Maria, Catalano, Lucio, Picca, Anna, D’Elia, Mariaelena, Biscotti, Damiano, Cauda, Roberto, Murri, Rita, Cingolani, Antonella, Ventura, Giulio, Taddei, Eleonora, Moschese, Davide, Ciccullo, Arturo, Stella, Leonardo, Addolorato, Giovanni, Franceschi, Francesco, Mingrone, Gertrude, Assunta Zocco, Maria, Sanguinetti, Maurizio, Cattani Franchi, Paola, Marchetti, Simona, Posteraro, Brunella, Sali, Michela, Bizzarro, Alessandra, Lauria, Alessandra, Rizzo, Stanislao, Savastano, Maria Cristina, Gambini, Gloria, Maria Cozzupoli, Grazia, Culiersi, Carola, Passali, Giulio Cesare, Paludetti, Gaetano, Galli, Jacopo, Crudo, Fabrizio, Di Cintio, Giovanni, Longobardi, Ylenia, Tricarico, Laura, Santantonio, Mariaconsiglia, Di Cesare, Tiziana, Guarino, Mariateresa, Corbò, Marco, Settimi, Stefano, Mele, Dario, Brigato, Francesca, Buonsenso, Danilo, Valentini, Piero, Sinatti, Dario, De Rose, Gabriella, Richeldi, Luca, Lombardi, Francesco, Calabrese, Angelo, Varone, Francesco, Maria Leone, Paolo, Siciliano, Matteo, Corbo, Giuseppe Maria, Montemurro, Giuliano, Calvello, Mariarosaria, Intini, Enrica, Simonetti, Jacopo, Pasciuto, Giuliana, Adiletta, Veronica, Sofia, Carmelo, Angela Licata, Maria, Sani, Gabriele, Janiri, Delfina, Simonetti, Alessio, Modica, Marco, Silvia, Montanari, Catinari, Antonello, Terenzi, Beatrice, Natale, Luigi, Larici, Anna Rita, Marano, Riccardo, Pirronti, Tommaso, Infante, Amato, Paglionico, Annamaria, Petricca, Luca, Tolusso, Barbara, Alivernini, Stefano, Di Mario, Clara, Santoliquido, Angelo, Santoro, Luca, Nesci, Antonio, Di Giorgio, Angela, D’Alessandro, Alessia, Matteo Tosato, Riccardo Calvani (ORCID:0000-0001-5472-2365), Francesca Ciciarello, Vincenzo Galluzzo, Anna Maria Martone, Maria Beatrice Zazzara, Giulia Savera, Francesco Landi (ORCID:0000-0002-3472-1389), Elisa Gremese (ORCID:0000-0002-2248-1058), Roberto Bernabei (ORCID:0000-0002-9197-004X), Massimo Fantoni (ORCID:0000-0001-6913-8460), Emanuele Marzetti (ORCID:0000-0001-9567-6983), Roberto Cauda (ORCID:0000-0002-1498-4229), Giulio Ventura (ORCID:0000-0002-0304-7264), Giovanni Addolorato (ORCID:0000-0002-1522-9946), Francesco Franceschi (ORCID:0000-0001-6266-445X), Maurizio Sanguinetti (ORCID:0000-0002-9780-7059), Paola Cattani (ORCID:0000-0003-4678-4763), Brunella Posteraro (ORCID:0000-0002-1663-7546), Stanislao Rizzo (ORCID:0000-0001-6302-063X), Maria Cristina Savastano (ORCID:0000-0003-1397-4333), Giulio Cesare Passali (ORCID:0000-0002-8176-0962), Jacopo Galli (ORCID:0000-0001-6353-6249), Piero Valentini (ORCID:0000-0001-6095-9510), Luca Richeldi (ORCID:0000-0001-8594-1448), Giuseppe Maria Corbo (ORCID:0000-0002-8104-4659), Gabriele Sani (ORCID:0000-0002-9767-8752), Luigi Natale (ORCID:0000-0002-7949-5119), Anna Rita Larici (ORCID:0000-0002-1882-6244), Riccardo Marano (ORCID:0000-0003-2710-2093), Stefano Alivernini (ORCID:0000-0002-7383-4212), Angelo Santoliquido (ORCID:0000-0003-1539-4017), Tosato, Matteo, Calvani, Riccardo, Ciciarello, Francesca, Galluzzo, Vincenzo, Martone, Anna Maria, Zazzara, Maria Beatrice, Pais, Cristina, Savera, Giulia, Camprubi Robles, Maria, Ramirez, Maria, Landi, Francesco, Gremese, Elisa, Bernabei, Roberto, Fantoni, Massimo, Gasbarrini, Antonio, Romano Settanni, Carlo, Porcari, Serena, Benvenuto, Francesca, Bramato, Giulia, Brandi, Vincenzo, Carfì, Angelo, Rita Lo Monaco, Maria, Maria Martone, Anna, Marzetti, Emanuele, Napolitano, Carmen, Pagano, Francesco, Rocchi, Sara, Rota, Elisabetta, Salerno, Andrea, Tritto, Marcello, Beatrice Zazzara, Maria, Catalano, Lucio, Picca, Anna, D’Elia, Mariaelena, Biscotti, Damiano, Cauda, Roberto, Murri, Rita, Cingolani, Antonella, Ventura, Giulio, Taddei, Eleonora, Moschese, Davide, Ciccullo, Arturo, Stella, Leonardo, Addolorato, Giovanni, Franceschi, Francesco, Mingrone, Gertrude, Assunta Zocco, Maria, Sanguinetti, Maurizio, Cattani Franchi, Paola, Marchetti, Simona, Posteraro, Brunella, Sali, Michela, Bizzarro, Alessandra, Lauria, Alessandra, Rizzo, Stanislao, Savastano, Maria Cristina, Gambini, Gloria, Maria Cozzupoli, Grazia, Culiersi, Carola, Passali, Giulio Cesare, Paludetti, Gaetano, Galli, Jacopo, Crudo, Fabrizio, Di Cintio, Giovanni, Longobardi, Ylenia, Tricarico, Laura, Santantonio, Mariaconsiglia, Di Cesare, Tiziana, Guarino, Mariateresa, Corbò, Marco, Settimi, Stefano, Mele, Dario, Brigato, Francesca, Buonsenso, Danilo, Valentini, Piero, Sinatti, Dario, De Rose, Gabriella, Richeldi, Luca, Lombardi, Francesco, Calabrese, Angelo, Varone, Francesco, Maria Leone, Paolo, Siciliano, Matteo, Corbo, Giuseppe Maria, Montemurro, Giuliano, Calvello, Mariarosaria, Intini, Enrica, Simonetti, Jacopo, Pasciuto, Giuliana, Adiletta, Veronica, Sofia, Carmelo, Angela Licata, Maria, Sani, Gabriele, Janiri, Delfina, Simonetti, Alessio, Modica, Marco, Silvia, Montanari, Catinari, Antonello, Terenzi, Beatrice, Natale, Luigi, Larici, Anna Rita, Marano, Riccardo, Pirronti, Tommaso, Infante, Amato, Paglionico, Annamaria, Petricca, Luca, Tolusso, Barbara, Alivernini, Stefano, Di Mario, Clara, Santoliquido, Angelo, Santoro, Luca, Nesci, Antonio, Di Giorgio, Angela, D’Alessandro, Alessia, Matteo Tosato, Riccardo Calvani (ORCID:0000-0001-5472-2365), Francesca Ciciarello, Vincenzo Galluzzo, Anna Maria Martone, Maria Beatrice Zazzara, Giulia Savera, Francesco Landi (ORCID:0000-0002-3472-1389), Elisa Gremese (ORCID:0000-0002-2248-1058), Roberto Bernabei (ORCID:0000-0002-9197-004X), Massimo Fantoni (ORCID:0000-0001-6913-8460), Emanuele Marzetti (ORCID:0000-0001-9567-6983), Roberto Cauda (ORCID:0000-0002-1498-4229), Giulio Ventura (ORCID:0000-0002-0304-7264), Giovanni Addolorato (ORCID:0000-0002-1522-9946), Francesco Franceschi (ORCID:0000-0001-6266-445X), Maurizio Sanguinetti (ORCID:0000-0002-9780-7059), Paola Cattani (ORCID:0000-0003-4678-4763), Brunella Posteraro (ORCID:0000-0002-1663-7546), Stanislao Rizzo (ORCID:0000-0001-6302-063X), Maria Cristina Savastano (ORCID:0000-0003-1397-4333), Giulio Cesare Passali (ORCID:0000-0002-8176-0962), Jacopo Galli (ORCID:0000-0001-6353-6249), Piero Valentini (ORCID:0000-0001-6095-9510), Luca Richeldi (ORCID:0000-0001-8594-1448), Giuseppe Maria Corbo (ORCID:0000-0002-8104-4659), Gabriele Sani (ORCID:0000-0002-9767-8752), Luigi Natale (ORCID:0000-0002-7949-5119), Anna Rita Larici (ORCID:0000-0002-1882-6244), Riccardo Marano (ORCID:0000-0003-2710-2093), Stefano Alivernini (ORCID:0000-0002-7383-4212), and Angelo Santoliquido (ORCID:0000-0003-1539-4017)

Abstract

Background: Nutritional status is a critical factor throughout COVID-19 disease course. Malnutrition is associated with poor outcomes in hospitalized COVID-19 patients. Aim: To assess the prevalence of malnutrition and identify its associated factors in COVID-19 survivors. Methods: Study cohort included 1230 COVID-19 survivors aged 18-86 attending a post-COVID-19 outpatient service. Data on clinical parameters, anthropometry, acute COVID-19 symptoms, lifestyle habits were collected through a comprehensive medical assessment. Malnutrition was assessed according to Global Leadership Initiative on Malnutrition (GLIM) criteria. Results: Prevalence of malnutrition was 22% at 4-5 months after acute disease. Participants who were not hospitalized during acute COVID-19 showed a higher frequency of malnutrition compared to those who needed hospitalization (26% versus 19%, p < 0.01). Malnutrition was found in 25% COVID-19 survivors over 65 years of age compared to 21% younger participants (p < 0.01). After multivariable adjustment, the likelihood of being malnourished increased progressively and independently with advancing age (Odds ratio [OR] 1.02; 95% CI 1.01-1.03) and in male participants (OR 5.56; 95% CI 3.53-8.74). Malnutrition was associated with loss of appetite (OR 2.50; 95% CI 1.73-3.62), and dysgeusia (OR 4.05; 95% CI 2.30-7.21) during acute COVID-19. Discussion: In the present investigation we showed that malnutrition was highly prevalent in a large cohort of COVID-19 survivors at 4-5 months from acute illness. Conclusions: Our findings highlight the need to implement comprehensive nutritional assessment and therapy as an integral part of care for COVID-19 patients.

Published
2023

79. Early use of tecovirimat in a young man with severe mpox skin lesions: a case report

Author

Iannone, Valentina, Ciccullo, Arturo, Farinacci, Damiano, Borghetti, Alberto, Visconti, Elena, Marchetti, Simona, Sanguinetti, Maurizio, Tamburrini, Enrica, Di Giambenedetto, Simona, Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Iannone, Valentina, Ciccullo, Arturo, Farinacci, Damiano, Borghetti, Alberto, Visconti, Elena, Marchetti, Simona, Sanguinetti, Maurizio, Tamburrini, Enrica, Di Giambenedetto, Simona, Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)

Abstract

N/A

Published
2023

80. Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic

Author

Delle Donne, Valentina, Massaroni, Valentina, Borghetti, Alberto, Ciccullo, Arturo, Dusina, Alex, Lombardi, Francesca, Steiner, Rebecca Jo, Iannone, Valentina, Salvo, Pierluigi Francesco, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Delle Donne, Valentina, Massaroni, Valentina, Borghetti, Alberto, Ciccullo, Arturo, Dusina, Alex, Lombardi, Francesca, Steiner, Rebecca Jo, Iannone, Valentina, Salvo, Pierluigi Francesco, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)

Abstract

Evidence accumulated during past years confirm that people living with HIV (PLWH) still have to deal with comorbidities and chronic complications that can increase physical and psychological issues and can affect daily functioning, quality of life and mental health. Moreover, during the COVID-19 pandemic PLWH proved to be a population at increased risk of psychological distress. We explored the ongoing issues and the characteristics of the mental health interventions for which a cohort of Italian PLWH interacted with a psychologist over the past five years. We analysed a dataset that included 61 PLWH who underwent a psychological intervention between 2018 and 2022. We compared different frequencies in characteristics of mental health interventions according to different demographic and clinical variables, psychopathological symptoms and time of the request for intervention. We showed that psychopathological symptoms most frequently reported by patients were anxiety (55.7%), and depression (49.2%). Furthermore, we reported that most our patients undertook occasional psychological support meetings (31%), sought an intervention after the outbreak of the COVID-19 pandemic (62.3%) and complained about disclosure issues (48.5%). Disclosure issues were mainly reported by younger PLWH (p = 0.002) with a shorter disease (p = 0.031) and treatment history (p = 0.032), and higher interpersonal sensitivity (p = 0.042). It seems fundamental to integrate psychological interventions into the care of PLWH, to give particular attention to PLWH with risky demographic, clinical and mental health factors and to pay special attention to emergency conditions (such as the COVID-19 pandemic) and the most widespread issues to create ad hoc interventions.

Published
2023

81. Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study

Author

Lombardi, Francesca, Sanfilippo, Alessia, Fabbiani, Massimiliano, Borghetti, Alberto, Ciccullo, Arturo, Tamburrini, Enrica, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Lombardi, Francesca, Sanfilippo, Alessia, Fabbiani, Massimiliano, Borghetti, Alberto, Ciccullo, Arturo, Tamburrini, Enrica, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)

Abstract

Background Blood telomere length (BTL) is a validated biomarker of aging. ART reduces immunosenescence and has benefits in terms of BTL in people living with HIV (PLWH). However, it has also been observed that ART containing NRTIs, such as tenofovir or abacavir, which are potent inhibitors of human telomerase activity in vitro, might negatively affect BTL. Here we investigated the effects on BTL 1 year after switching to a dual therapy (DT) with dolutegravir + lamivudine versus maintaining a standard triple therapy (TT) with a two-NRTI backbone and an anchor drug. Methods This was a longitudinal, prospective, matched, controlled study that included virologically suppressed adults on stable three-drug ART who either switched at baseline (BL) to DT or maintained TT. The DT and TT groups were 1:1 matched for age, sex, years since HIV diagnosis, years on ART and anchor drug. BTL was assessed by a monochrome multiplex qPCR at BL and after 48 weeks (W48). Results We enrolled 120 PLWH, i.e. 60 participants in each group. At BL, the BTL means were comparable between the two groups (P = 0.973). At W48, viro-immunological status was stable and an overall increase in the mean BTL was observed, i.e., +0.161 (95%CI, 0.054-0.268) (P = 0.004). However, the within-group analysis showed a significant mean BTL gain in the DT group (P = 0.003) but not in the TT group (P = 0.656). Conclusions In this setting of virologically suppressed PLWH, simplifying to dolutegravir + lamivudine was associated with a higher gain in BTL than maintaining triple therapy after the 1 year follow-up. These findings suggest that as a simplification strategy dolutegravir + lamivudine might have a positive effect on BTL.

Published
2023

82. Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen

Author

Iannone, Valentina, Passerotto, Rosa Anna, Lamanna, Francesco, Steiner, Rebecca Jo, Lombardi, Francesca, Salvo, Pierluigi Francesco, Dusina, Alex, Farinacci, Damiano, Borghetti, Alberto, Di Giambenedetto, Simona, Ciccullo, Arturo, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Iannone, Valentina, Passerotto, Rosa Anna, Lamanna, Francesco, Steiner, Rebecca Jo, Lombardi, Francesca, Salvo, Pierluigi Francesco, Dusina, Alex, Farinacci, Damiano, Borghetti, Alberto, Di Giambenedetto, Simona, Ciccullo, Arturo, Lombardi, Francesca (ORCID:0000-0001-5757-8346), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)

Abstract

Thanks to the modern ARV regimens and the fact that the morbidity and mortality of metabolic syndrome increases with age, clinicians are continuously researching effective and safe antiretroviral regimens with low impact on the lipid profile. Doravirine (DOR) is the latest non-nucleoside reverse-transcriptase inhibitor (NNRTI) that shows long-term safety and tolerability and a favorable lipid profile. The aim of this study is to assess the impact of DOR-based three-drug regimens on the lipid profile in clinical practice. We retrospectively analyzed a cohort of 38 treatment-experienced, virologically suppressed people living with HIV (PLWH) switching to this regimen, following the eligibility criteria. We carried out comparison analysis of immunological and metabolic parameters between baseline and 48 weeks of follow up. In our cohort of treatment-experienced, virologically suppressed PLWH, three-drug regimens with DOR showed good efficacy and a positive profile on lipid metabolism at 48 weeks of follow up.

Published
2023

83. Rapid improvement of severe Mpox lesions with oral tecovirimat

Author

Angelo Roberto Raccagni, Davide Leoni, Arturo Ciccullo, Stefano Verdenelli, Anna Maria Cattelan, Simona Di Giambenedetto, Marco Falcone, Davide Mileto, Antonella Castagna, and Silvia Nozza

Subjects
Infectious Diseases, Virology
Published
2023

85. Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life

Author

Valentina Iannone, Damiano Farinacci, Anna D'Angelillo, Alex Dusina, Francesco Lamanna, Rosanna Passerotto, Gianmaria Baldin, Elena Visconti, Enrica Tamburrini, Alberto Borghetti, Simona Di Giambenedetto, and Arturo Ciccullo

Subjects
HAART, Anti-HIV Agents, cardiovascular, Immunology, HIV, HIV Infections, Cholesterol, LDL, CVD, Settore MED/17 - MALATTIE INFETTIVE, Infectious Diseases, Cardiovascular Diseases, Virology, doravirine, HIV-1, Humans, Retrospective Studies, Preliminary Data
Abstract

Aim of this study is to assess the impact of doravirine (DOR)-based regimens on cardiovascular risk in treatment-experienced people living with HIV (PLWHIV). We retrospectively analyzed a cohort of 40 treatment-experienced PLWHIV switching to a DOR-based three-drug regimen, evaluating 10-year risk of manifesting clinical cardiovascular diseases (CD) through the Framingham Risk Score at baseline, 12, and 24 weeks of follow-up. At baseline, median predicted 10-year risk of cardiovascular disease (10Y-CD) was 8.0% (interquartile range 4.0-13.0). After 12 weeks, we observed a significant reduction in 10Y-CD (mean decrease -2.21

Published
2022

86. Traceability for sustainability: seeking legitimacy in the coffee supply chain

Author

Verónica León-Bravo, Federica Ciccullo, and Federico Caniato

Subjects
Legitimacy theory, Coffee industry, Sustainability, Business, Management and Accounting (miscellaneous), Traceability, Food Science
Abstract

PurposeThe adoption of traceability systems (TS) and sustainability programs responds to different objectives among which the companies need to be considered legitimate; hence, this study aims, first, to identify what is the relationship between traceability and sustainability in the food supply chain (SC) and, second, to characterize the legitimacy-seeking purposes, i.e. moral, cogniti60ve or pragmatic-driving companies to implement TS along with sustainability initiatives.Design/methodology/approachThis study analyses the coffee SC, a globally dispersed commodity chain, where traceability initiatives usually respond to mandatory and voluntary quality standards and certifications of origin. The study involves nine cases at different stages of the coffee SC.FindingsThis study provides a taxonomy of the TS applied in the coffee SC. In addition, three main approaches to traceability for sustainability are found in the coffee SC: synergistic, complementary or disconnected. Findings also reveal how traceability responds to different legitimacy-seeking objectives while triggering or complementing sustainability practices. Five research propositions and related directions for further investigations are elaborated from the results of our study.Originality/valueThis study explores a rather limited studied area, investigating how companies in a food commodity chain address traceability and sustainability together while seeking legitimacy in the market. Moreover, the study is grounded on legitimacy theory, thus adding robustness to the analysis.

Published
2022

88. Reduced probability of improving viro‐immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study

Author

Pennati, Francesca, primary, Calza, Stefano, additional, Di Biagio, Antonio, additional, Mussini, Cristina, additional, Rusconi, Stefano, additional, Bonora, Stefano, additional, Borghetti, Alberto, additional, Quiros‐Roldan, Eugenia , additional, Sarteschi, Giovanni, additional, Menozzi, Marianna, additional, Ferrara, Micol, additional, Celotti, Anna, additional, Ciccullo, Arturo, additional, Giacomet, Vania, additional, Izzo, Ilaria, additional, Dotta, Laura, additional, Badolato, Raffaele, additional, Castelli, Francesco, additional, and Focà, Emanuele, additional

Published
2023
Full Text
View/download PDF

90. HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV

Author

Valentina Massaroni, Valentina Delle Donne, Nicoletta Ciccarelli, Francesca Lombardi, Silvia Lamonica, Alberto Borghetti, Arturo Ciccullo, and Simona Di Giambenedetto

Subjects
stigma, Settore M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA, education, patient health engagement model, HIV infection, health care, General Psychology, engagement
Abstract

The care engagement of people living with HIV (PLWH) measured with the patient health engagement (PHE) model and its association with HIV-related internalized stigma are not well established. Indeed, currently there are no data yet about the engagement of PLWH measured with the PHE model. This study aimed to evaluate the effects of HIV-related internalized stigma on care engagement and mental health and to fill the lack of data on PHE model applied to PLWH. We found that the internalized stigma score was significantly higher for PLWH ( n=82) in worse care engagement phase and both higher internalized stigma scores and worse engagement were associated to major depression symptoms. In conclusion, our findings describe for the first time the engagement in care of PLWH measured with PHE and highlight the importance of PLWH support to find strategies to cope stigma-related stress and optimize their care engagement.

Published
2022

92. Does the combination of sustainable business model patterns lead to truly sustainable business models? Critical analysis of existing frameworks and extensions

Author

Nizar Abdelkafi, Jinou Xu, Margherita Pero, Federica Ciccullo, and Antonio Masi

Subjects
Economics and Econometrics, Sustainability, Business and International Management, Business model pattern, Sustainable business model, Business model
Abstract

Business models can be created by combining business model patterns. The use of patterns can stimulate creativity of entrepreneurs and support the design of innovative business models for sustainability. In this article, we analyze the frameworks on sustainable business model (SBM) patterns, which can be mainly classified along the three dimensions of the triple bottom line (TBL): economic, environmental, and social. Furthermore, we introduce the concept of “truly sustainable business models” by drawing on contingency and system theory. We observe that the simple application of the frameworks of business model patterns by combining economic, environmental, and social business model patterns for sustainability into one single business model does not necessarily lead to a truly sustainable business model. Therefore, the combination of patterns along the TBL seems a necessary, but not sufficient condition for achieving true sustainability, and hence, the mere reliance on SBM patterns in business model design can be misleading to entrepreneurs. Our conceptual work advances research related to frameworks on SBM patterns by identifying three critical levels for the analysis of whether a business model is truly sustainable or not. The first level is inherent to the business model as a system; the second is related to the larger system, in which the business model is embedded; and the third is about the contingency factors that can impact the sustainability effectiveness of the business model over time.

Published
2023

93. Analyzing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicenter cohort of virologically-suppressed PLWHIV

Author

A Ciccullo, G Baldin, V Borghi, M V Cossu, A Giacomelli, F Lagi, D Farinacci, V Iannone, R A Passerotto, A Capetti, G Sterrantino, C Mussini, S Antinori, and S Di Giambenedetto

Subjects
Pharmacology, Microbiology (medical), Infectious Diseases, Settore MED/17 - Malattie Infettive, Pharmacology (medical)
Abstract

Objectives We aimed to investigate and compare the efficacy and safety of two dolutegravir-based two-drug regimens: dolutegravir + lamivudine versus dolutegravir + rilpivirine. Methods We analysed a cohort of people living with HIV (PLWHIV) switching to dolutegravir + lamivudine or dolutegravir + rilpivirine. We excluded from the analysis PLWHIV with no available pre-switch genotypic test or with a known resistance mutation to one of the study drugs. We evaluated incidence of virological failure (VF) and treatment discontinuation (TD), as well as changes in immunological and metabolic parameters. Results We enrolled 592 PLWHIV: 306 in the lamivudine group and 286 in the rilpivirine group. We observed nine VFs in the lamivudine group [1.4 VF per 100 patient-years of follow-up (PYFU)] and four VFs in the rilpivirine group (0.6 VF per 100 PYFU). Subsequent genotypic analysis showed no acquired resistance-associated mutations in those experiencing VF. Estimated probability of maintaining virological suppression at 144 and 240 weeks were 96.6% and 92.7%, respectively, in the lamivudine group and 98.7% and 98.7%, respectively, in the rilpivirine group (log-rank P = 0.172). The estimated probability of maintaining study regimen at Week 240 was 82.3% in the lamivudine group and 85.9% in the rilpivirine group (log-rank P = 0.018). We observed a significant improvement in CD4+ cell count at Week 240 in the lamivudine group (P = 0.012); in the rilpivirine group we registered a significant increase in CD4/CD8 ratio (P = 0.014). Conclusions Both analysed strategies are effective and safe as switch strategies in clinical practice, with a low incidence of VF and a favourable immunological recovery, even in the long term.

Published
2023

94. Sustainable innovation in the dairy supply chain: enabling factors for intermodal transportation.

Author

Cannas, Violetta Giada, Ciccullo, Federica, Pero, Margherita, and Cigolini, Roberto

Subjects
CONTAINERIZATION, SUPPLY chains, BUSINESS logistics, INTERMODAL freight terminals, BUSINESS models, TRANSPORTATION industry
Abstract

There is a need for the dairy supply chain to improve its environmental performance. Intermodal rail-road transportation can be a way to reduce CO2 emissions. However, despite technological innovations in the realm of cooling technology, which could enable a shift to intermodal transportation, the use of intermodal rail-road in the dairy supply chain is still low. A blueprint is needed to foster the application of intermodal transportation in the sector. Literature provides little guidance in this sense. Therefore, this paper investigates how to ease the shift to intermodal rail-road transportation in the dairy supply chain through multiple case studies, performed at different stages of the supply chain. A set of enablers of the shift is discussed, along with a blueprint for innovative technology, and logistics and business models. The plan takes into account all the actors of the dairy industry, as well as other players, i.e. technology providers, academia and institutions. This paper enriches literature, thanks to its multi-stage research, providing managers with a practical tool to support the shift to intermodal transportation in the dairy industry. The main limitations lay in the choice of the sample, i.e. only Italian companies and no small retailers and farmers have been involved. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

95. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Author

Andrea Giacometti, Gabriella d'Ettorre, Amedeo Capetti, William Gennari, Stefano Rusconi, Gaetana Sterrantino, Andrea Giacomelli, Vanni Borghi, Gianmaria Baldin, Alessandra Latini, Andrea De Vito, Cristina Mussini, Arturo Ciccullo, Simona Di Giambenedetto, Giordano Madeddu, and Maria Vittoria Cossu

Subjects
Male, medicine.medical_specialty, HAART, Anti-HIV Agents, Pyridones, HIV Infections, 3-Ring, Settore MED/17 - MALATTIE INFETTIVE, Piperazines, chemistry.chemical_compound, Heterocyclic Compounds, Interquartile range, Internal medicine, HIV Seropositivity, Oxazines, medicine, Humans, Pharmacology (medical), Survival analysis, Retrospective Studies, business.industry, HIV, Lamivudine, Retrospective cohort study, Middle Aged, dolutegravir, Discontinuation, Regimen, Infectious Diseases, Tolerability, chemistry, Dolutegravir, RNA, Female, business, Heterocyclic Compounds, 3-Ring, medicine.drug
Abstract

BACKGROUND Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1-positive patients. We aimed to assess long-time efficacy and safety in our multicenter cohort. METHODS This was a retrospective study enrolling HIV-1-infected, virologically suppressed patients switching to dolutegravir + lamivudine. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥1000 copies/mL or by 2 consecutive HIV-RNA ≥ 50 copies/mL) and treatment discontinuation (defined as the interruption of either 3TC or dolutegravir), assessing predictors via Cox regression analyses. RESULTS Seven-hundred eighty-five patients were considered for the analysis: 554 were men (70.6%), with a median age of 52 years (interquartile range 45-58 years). Estimated probabilities of maintaining virological suppression at weeks 96, 144, and 240 were 97.7% (SD ±0.6), 96.9% (SD ±0.8), and 96.4% (SD ±0.9), respectively. A non-B HIV subtype (P = 0.014) and a previous VF (P = 0.037) resulted predictors of VF. We did not observe differences in probability of VF in people living with HIV with an M184V resistance mutation (P = 0.689); however, in a deeper analysis, M184V mutation was a predictor of VF (P = 0.038) in patients with time of virological suppression

Published
2021

96. Is smallpox vaccination protective against human monkeypox?

Author

Davide Moschese, Damiano Farinacci, Giacomo Pozza, Arturo Ciccullo, Maria Vittoria Cossu, Andrea Giacomelli, Fabio Borgonovo, Davide Mileto, Rosaria Santangelo, Enrica Tamburrini, Giuliano Rizzardini, Spinello Antinori, and Simona Di Giambenedetto

Subjects
Infectious Diseases, N/A, Virology, Settore MED/17 - MALATTIE INFETTIVE
Published
2022

97. Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV

Author

Ciccullo, A, primary, Baldin, G, additional, Borghi, V, additional, Cossu, M V, additional, Giacomelli, A, additional, Lagi, F, additional, Farinacci, D, additional, Iannone, V, additional, Passerotto, R A, additional, Capetti, A, additional, Sterrantino, G, additional, Mussini, C, additional, Antinori, S, additional, and Di Giambenedetto, S, additional

Published
2022
Full Text
View/download PDF

98. Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life

Author

Iannone, Valentina, primary, Farinacci, Damiano, additional, D'Angelillo, Anna, additional, Dusina, Alex, additional, Lamanna, Francesco, additional, Passerotto, Rosanna, additional, Baldin, Gianmaria, additional, Visconti, Elena, additional, Tamburrini, Enrica, additional, Borghetti, Alberto, additional, Di Giambenedetto, Simona, additional, and Ciccullo, Arturo, additional

Published
2022
Full Text
View/download PDF

99. Is smallpox vaccination protective against human monkeypox?

Author

Moschese, Davide, primary, Farinacci, Damiano, additional, Pozza, Giacomo, additional, Ciccullo, Arturo, additional, Cossu, Maria Vittoria, additional, Giacomelli, Andrea, additional, Borgonovo, Fabio, additional, Mileto, Davide, additional, Santangelo, Rosaria, additional, Tamburrini, Enrica, additional, Rizzardini, Giuliano, additional, Antinori, Spinello, additional, and Giambenedetto, Simona Di, additional

Published
2022
Full Text
View/download PDF

100. Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Author

Di Castelnuovo, A, Costanzo, S, Antinori, A, Berselli, N, Blandi, L, Bonaccio, M, Bruno, R, Cauda, R, Gialluisi, A, Guaraldi, G, Menicanti, L, Mennuni, M, My, I, Parruti, A, Patti, G, Perlini, S, Santilli, F, Signorelli, C, Stefanini, G, Vergori, A, Ageno, W, Aiello, L, Agostoni, P, Al Moghazi, S, Arboretti, R, Aucella, F, Barbieri, G, Barchitta, M, Bartoloni, A, Bologna, C, Bonfanti, P, Caiano, L, Carrozzi, L, Cascio, A, Castiglione, G, Chiarito, M, Ciccullo, A, Cingolani, A, Cipollone, F, Colomba, C, Colombo, C, Crosta, F, Dalena, G, Dal Pra, C, Danzi, G, D'Ardes, D, de Gaetano Donati, K, Di Gennaro, F, Di Tano, G, D'Offizi, G, Filippini, T, Maria Fusco, F, Gaudiosi, C, Gentile, I, Gini, G, Grandone, E, Guarnieri, G, Lamanna, G, Larizza, G, Leone, A, Lio, V, Losito, A, Maccagni, G, Maitan, S, Mancarella, S, Manuele, R, Mapelli, M, Maragna, R, Marra, L, Maresca, G, Marotta, C, Mastroianni, F, Mazzitelli, M, Mengozzi, A, Menichetti, F, Milic, J, Minutolo, F, Molena, B, Mussinelli, R, Mussini, C, Musso, M, Odone, A, Olivieri, M, Pasi, E, Perroni, A, Petri, F, Pinchera, B, Pivato, C, Poletti, V, Ravaglia, C, Rossato, M, Rossi, M, Sabena, A, Salinaro, F, Sangiovanni, V, Sanrocco, C, Scorzolini, L, Sgariglia, R, Simeone, P, Spinicci, M, Trecarichi, E, Veronesi, G, Vettor, R, Vianello, A, Vinceti, M, Visconti, E, Vocciante, L, De Caterina, R, Iacoviello, L, Di Castelnuovo, Augusto, Costanzo, Simona, Antinori, Andrea, Berselli, Nausicaa, Blandi, Lorenzo, Bonaccio, Marialaura, Bruno, Raffaele, Cauda, Roberto, Gialluisi, Alessandro, Guaraldi, Giovanni, Menicanti, Lorenzo, Mennuni, Marco, My, Ilaria, Parruti, Agostino, Patti, Giuseppe, Perlini, Stefano, Santilli, Francesca, Signorelli, Carlo, Stefanini, Giulio G, Vergori, Alessandra, Ageno, Walter, Aiello, Luca, Agostoni, Piergiuseppe, Al Moghazi, Samir, Arboretti, Rosa, Aucella, Filippo, Barbieri, Greta, Barchitta, Martina, Bartoloni, Alessandro, Bologna, Carolina, Bonfanti, Paolo, Caiano, Lucia, Carrozzi, Laura, Cascio, Antonio, Castiglione, Giacomo, Chiarito, Mauro, Ciccullo, Arturo, Cingolani, Antonella, Cipollone, Francesco, Colomba, Claudia, Colombo, Crizia, Crosta, Francesco, Dalena, Giovanni, Dal Pra, Chiara, Danzi, Gian Battista, D'Ardes, Damiano, de Gaetano Donati, Katleen, Di Gennaro, Francesco, Di Tano, Giuseppe, D'Offizi, Gianpiero, Filippini, Tommaso, Maria Fusco, Francesco, Gaudiosi, Carlo, Gentile, Ivan, Gini, Giancarlo, Grandone, Elvira, Guarnieri, Gabriella, Lamanna, Gennaro L F, Larizza, Giovanni, Leone, Armando, Lio, Veronica, Losito, Angela Raffaella, Maccagni, Gloria, Maitan, Stefano, Mancarella, Sandro, Manuele, Rosa, Mapelli, Massimo, Maragna, Riccardo, Marra, Lorenzo, Maresca, Giulio, Marotta, Claudia, Mastroianni, Franco, Mazzitelli, Maria, Mengozzi, Alessandro, Menichetti, Francesco, Milic, Jovana, Minutolo, Filippo, Molena, Beatrice, Mussini, Cristina, Musso, Maria, Odone, Anna, Olivieri, Marco, Pasi, Emanuela, Perroni, Annalisa, Petri, Francesco, Pinchera, Biagio, Pivato, Carlo A, Poletti, Venerino, Ravaglia, Claudia, Rossato, Marco, Rossi, Marianna, Sabena, Anna, Salinaro, Francesco, Sangiovanni, Vincenzo, Sanrocco, Carlo, Scorzolini, Laura, Sgariglia, Raffaella, Simeone, Paola Giustina, Spinicci, Michele, Trecarichi, Enrico Maria, Veronesi, Giovanni, Vettor, Roberto, Vianello, Andrea, Vinceti, Marco, Visconti, Elena, Vocciante, Laura, De Caterina, Raffaele, Iacoviello, Licia, Di Castelnuovo, A, Costanzo, S, Antinori, A, Berselli, N, Blandi, L, Bonaccio, M, Bruno, R, Cauda, R, Gialluisi, A, Guaraldi, G, Menicanti, L, Mennuni, M, My, I, Parruti, A, Patti, G, Perlini, S, Santilli, F, Signorelli, C, Stefanini, G, Vergori, A, Ageno, W, Aiello, L, Agostoni, P, Al Moghazi, S, Arboretti, R, Aucella, F, Barbieri, G, Barchitta, M, Bartoloni, A, Bologna, C, Bonfanti, P, Caiano, L, Carrozzi, L, Cascio, A, Castiglione, G, Chiarito, M, Ciccullo, A, Cingolani, A, Cipollone, F, Colomba, C, Colombo, C, Crosta, F, Dalena, G, Dal Pra, C, Danzi, G, D'Ardes, D, de Gaetano Donati, K, Di Gennaro, F, Di Tano, G, D'Offizi, G, Filippini, T, Maria Fusco, F, Gaudiosi, C, Gentile, I, Gini, G, Grandone, E, Guarnieri, G, Lamanna, G, Larizza, G, Leone, A, Lio, V, Losito, A, Maccagni, G, Maitan, S, Mancarella, S, Manuele, R, Mapelli, M, Maragna, R, Marra, L, Maresca, G, Marotta, C, Mastroianni, F, Mazzitelli, M, Mengozzi, A, Menichetti, F, Milic, J, Minutolo, F, Molena, B, Mussinelli, R, Mussini, C, Musso, M, Odone, A, Olivieri, M, Pasi, E, Perroni, A, Petri, F, Pinchera, B, Pivato, C, Poletti, V, Ravaglia, C, Rossato, M, Rossi, M, Sabena, A, Salinaro, F, Sangiovanni, V, Sanrocco, C, Scorzolini, L, Sgariglia, R, Simeone, P, Spinicci, M, Trecarichi, E, Veronesi, G, Vettor, R, Vianello, A, Vinceti, M, Visconti, E, Vocciante, L, De Caterina, R, Iacoviello, L, Di Castelnuovo, Augusto, Costanzo, Simona, Antinori, Andrea, Berselli, Nausicaa, Blandi, Lorenzo, Bonaccio, Marialaura, Bruno, Raffaele, Cauda, Roberto, Gialluisi, Alessandro, Guaraldi, Giovanni, Menicanti, Lorenzo, Mennuni, Marco, My, Ilaria, Parruti, Agostino, Patti, Giuseppe, Perlini, Stefano, Santilli, Francesca, Signorelli, Carlo, Stefanini, Giulio G, Vergori, Alessandra, Ageno, Walter, Aiello, Luca, Agostoni, Piergiuseppe, Al Moghazi, Samir, Arboretti, Rosa, Aucella, Filippo, Barbieri, Greta, Barchitta, Martina, Bartoloni, Alessandro, Bologna, Carolina, Bonfanti, Paolo, Caiano, Lucia, Carrozzi, Laura, Cascio, Antonio, Castiglione, Giacomo, Chiarito, Mauro, Ciccullo, Arturo, Cingolani, Antonella, Cipollone, Francesco, Colomba, Claudia, Colombo, Crizia, Crosta, Francesco, Dalena, Giovanni, Dal Pra, Chiara, Danzi, Gian Battista, D'Ardes, Damiano, de Gaetano Donati, Katleen, Di Gennaro, Francesco, Di Tano, Giuseppe, D'Offizi, Gianpiero, Filippini, Tommaso, Maria Fusco, Francesco, Gaudiosi, Carlo, Gentile, Ivan, Gini, Giancarlo, Grandone, Elvira, Guarnieri, Gabriella, Lamanna, Gennaro L F, Larizza, Giovanni, Leone, Armando, Lio, Veronica, Losito, Angela Raffaella, Maccagni, Gloria, Maitan, Stefano, Mancarella, Sandro, Manuele, Rosa, Mapelli, Massimo, Maragna, Riccardo, Marra, Lorenzo, Maresca, Giulio, Marotta, Claudia, Mastroianni, Franco, Mazzitelli, Maria, Mengozzi, Alessandro, Menichetti, Francesco, Milic, Jovana, Minutolo, Filippo, Molena, Beatrice, Mussini, Cristina, Musso, Maria, Odone, Anna, Olivieri, Marco, Pasi, Emanuela, Perroni, Annalisa, Petri, Francesco, Pinchera, Biagio, Pivato, Carlo A, Poletti, Venerino, Ravaglia, Claudia, Rossato, Marco, Rossi, Marianna, Sabena, Anna, Salinaro, Francesco, Sangiovanni, Vincenzo, Sanrocco, Carlo, Scorzolini, Laura, Sgariglia, Raffaella, Simeone, Paola Giustina, Spinicci, Michele, Trecarichi, Enrico Maria, Veronesi, Giovanni, Vettor, Roberto, Vianello, Andrea, Vinceti, Marco, Visconti, Elena, Vocciante, Laura, De Caterina, Raffaele, and Iacoviello, Licia

Abstract

Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients. Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients. Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of treatment weighting by multinomial propensity scores. Results: Out of 3,451 patients, 33.3% LPV/r and 13.9% received DRV/c. Patients receiving LPV/r or DRV/c were more likely younger, men, had higher C-reactive protein levels while less likely had hypertension, cardiovascular, pulmonary or kidney disease. After adjustment for propensity scores, LPV/r use was not associated with mortality (HR = 0.94, 95% CI 0.78 to 1.13), whereas treatment with DRV/c was associated with a higher death risk (HR = 1.89, 1.53 to 2.34, E-value = 2.43). This increased risk was more marked in women, in elderly, in patients with higher severity of COVID-19 and in patients receiving other COVID-19 drugs. Conclusions: In a large cohort of Italian patients hospitalized for COVID-19 in a real-life setting, the use of LPV/r treatment did not change death rate, while DRV/c was associated with increased mortality. Within the limits of an observational study, these data do not support the use of LPV/r or DRV/c in COVID-19 patients.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results